Pharma and healthcare: sector news on Wednesday 28 October 2026
Average tone +3.5 (positive) across 5 companies with relevant coverage, from 65 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +7.5 | 33 | Coverage was dominated by EU clearance for Enhertu to treat HER2-positive breast cancer at an early stage, alongside an approval of Trixeo for adolescents with asthma and positive lung cancer trial results. |
| GSK | +7.0 | 23 | Coverage centred on GSK's intention to raise the number of its cancer drugs in trials to nearly twice the current level next year, along with upbeat late-stage results for the osteosarcoma treatment it developed with Hansoh. |
| Haleon | +1.3 | 5 | Coverage was mostly previews of Haleon's upcoming quarterly trading update, with Goldman Sachs keeping a Buy rating. |
| Convatec | −5.5 | 3 | Coverage mainly concerned a Court of Appeal ruling in a patent dispute between an inventor and Convatec, which appears to have gone against the company. |
| Smith & Nephew | +7.0 | 1 | Smith & Nephew was the subject of one relevant article, which linked a share price rise to expectations that hospitals could receive extra money in the Budget. |
Strongest stories in the sector
- +10.0 EU clearance for post-treatment use in early HER2-positive disease.
- +10.0 European regulator clears Enhertu for early breast cancer, widening its market.
- +10.0 Lung cancer combination substantially lowers mortality risk in trial.
- +10.0 Approval backed by large reduction in recurrence risk.
- +10.0 Approval supported by substantial reduction in recurrence or death risk.
- +9.7 Enhertu secures European go-ahead in early breast cancer.
- +9.7 Enhertu gains European approval.
- +9.7 Regulatory clearance in Europe for early breast cancer use.
- +9.5 Company's own regulatory announcement of EU clearance.
- +9.5 Official notice of adjuvant approval in Europe.
- +9.2 European authorisation granted for key cancer drug.
- +9.2 Successful late-stage cancer trial results; momentum question raised.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.